Michael Kranda

Michael Kranda has a diverse range of work experience in the biotech and pharmaceutical industries. Michael is currently the Chief Executive Officer and Director at LifeSprout, a clinical stage company focused on developing products for aesthetic and regenerative medicine applications. Prior to this, they served as the SVP CNS Practice Lead and Head of Alliance Management at Asklepios BioPharmaceutical, Inc. (AskBio), where they led strategic direction and operations for their CNS portfolio.

Before their role at AskBio, Michael was the Senior Director of Business Development at the Allen Institute. Michael also has experience as the CEO of BEAT BioTherapeutics and served as a Board Member and Audit Committee Chairman at PTC Therapeutics, Inc.

Michael has held leadership positions at various other companies, including Cardero Therapeutics, Vaccinogen Inc., Raven Biotechnologies, Vulcan Capital Management, and Oxford GlycoSciences. At Oxford GlycoSciences, they were the CEO and Director, leading strategy, business development, and fundraising efforts. Michael successfully achieved marketing approval for the rare orphan drug Zavesca and took the company public on the LSE and NASDAQ.

Overall, Michael Kranda has extensive experience in executive leadership, business development, and strategic management within the biotech and pharmaceutical industries.

Michael Kranda obtained an MBA with a specialization in Finance from the University of Washington. Michael pursued their degree between 1982 and 1984.